GLPwatch
Efficacy and safety of semaglutide in a diabetic and obese patient on incremental hemodialysis. Does it also contribute to preserving residual renal function?
Nefrologia (Engl Ed) · 2023
Last updated 2026-09-22| Journal | Nefrologia (Engl Ed), 2023 |
|---|---|
| Citations | 1 |
| Relative citation ratio | 0.08 |
| NIH percentile | 6 |
| Molecules | semaglutide |
| Conditions studied | Type 2 Diabetes, Obesity, Chronic Kidney Disease |
Full record and abstract on PubMed 37658008 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.